News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PAION: Phase Ib and IIa Studies of the Anesthetic/Sedative CNS 7056 on Track



7/15/2009 9:19:49 AM

AACHEN, Germany--(BUSINESS WIRE)--The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that the respective Data Monitoring Committees (DMCs), after predefined interim analyses, recommended that the Company should proceed as planned with their Phase IIa study as well as Phase Ib of CNS 7065, a new short-acting intravenous anesthetic/sedative.

Read at BioSpace.com


comments powered by Disqus
PAION AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES